Comparison of cystic fibrosis-related diabetes with type 1 diabetes based on a German/Austrian pediatric diabetes registry

Diabetes Care

Volumn 36, Issue 4, 2013, Pages 879-886

  Konrad, Katja ^a   Thon, Angelika ^b   Fritsch, Maria ^c   Fröhlich Reiterer, Elke ^d   Lilienthal, Eggert ^e   Wudy, Stefan A ^f   Holl, Reinhard W ^g  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f JUSTUS LIEBIG UNIVERSITY   (Germany)

^g UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GLINIDE DERIVATIVE; HEMOGLOBIN A1C; INSULIN DERIVATIVE; LONG ACTING INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SHORT ACTING INSULIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; AUSTRIA; BLOOD GLUCOSE MONITORING; BODY MASS; CHILD; CONTINUOUS INFUSION; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED DIABETES; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE DURATION; DISEASE REGISTRY; FEMALE; FOLLOW UP; GERMANY; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRESCHOOL CHILD; SCHOOL CHILD; SEX RATIO;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; REGISTRIES;

EID: 84875449728     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0807     Document Type: Article

References (38)

1. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005;146:681-687
2. Laguna TA, Nathan BM, Moran A. Managing diabetes in cystic fibrosis. Diabetes Obes Metab 2010;12:858-864
3. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009;32:1626-1631
4. Hameed S, Jaffé A, Verge CF. Cystic fibrosis related diabetes (CFRD)dthe end stage of progressive insulin deficiency. Pediatr Pulmonol 2011;46:747-760
5. O'Riordan SM, Robinson PD, Donaghue KC, Moran A. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2009;10 (Suppl 12):43-50
6. Godbout A, Hammana I, Potvin S, et al. No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes. Diabetes Metab 2008;34:568-573
7. Holl RW, Buck C, Babka C, Wolf A, Thon A. HbA1c is not recommended as a screening test for diabetes in cystic fibrosis. Diabetes Care 2000;23:126
8. Moran A, Becker D, Casella SJ, et al.; CFRD Consensus Conference Committee. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosisrelated diabetes: a technical review. Diabetes Care 2010;33:2677-2683
9. Bismuth E, Laborde K, Taupin P, Velho G, Ribault V, Jennane F, Grasset E, Sermet I, de Blic J, Lenoir G, Robert JJ, Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr 2008;152:540-545, 545 e1
10. Holl RW, Wolf A, Thon A, et al. Insulin resistance with altered secretory kinetics and reduced proinsulin in cystic fibrosis patients. J Pediatr Gastroenterol Nutr 1997;25:188-193
11. Blackman SM, Hsu S, Vanscoy LL, et al. Geneticmodifiers play a substantial role in diabetes complicating cystic fibrosis. J Clin Endocrinol Metab 2009;94:1302-130
12. RolonMA, Benali K, Munck A, et al. Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr 2001;90: 860-867
13. Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin improves clinical status of patients with cystic-fibrosisrelated diabetes mellitus. Acta Paediatr 2001;90:515-519
14. Moran A, Brunzell C, Cohen RC, et al.; CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33:2697-2708
15. Schwab KO, Doerfer J, Marg W, Schober E, Holl RW; DPV Science Initiative and the Competence Network Diabetes mellitus. Characterization of 33 488 children and adolescents with type 1 diabetes based on the gender-specific increase of cardiovascular risk factors. Pediatr Diabetes 2010;11:357-363
16. Grabert M, Schweiggert F, Holl RW. A framework for diabetes documentation and quality management in Germany: 10 years of experience with DPV. Comput Methods Programs Biomed 2002;69:115-121
17. Kromeyer-Hauschild K, Wabitsch M, Kunze D, et al. Perzentile für Body-mass-Index für das Kindes-und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschr Kinderheilkd 2001;149:807-818
18. Lai HJ. Classification of nutritional status in cystic fibrosis. Curr Opin Pulm Med 2006;12:422-427
19. Urbina E, Alpert B, Flynn J, et al.; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee. Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the council on cardiovascular disease in the young and the council for high blood pressure research. Hypertension 2008;52:433-451
20. Gerstl EM, Rabl W, Rosenbauer J, et al. Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27, 035 patients from207 centers in Germany and Austria during the last decade. Eur J Pediatr 2008;167:447-453
21. Hannon TS, Janosky J, Arslanian SA. Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. Pediatr Res 2006;60:759-763
22. Reinehr T, Holl RW, Roth CL, et al; DPVWiss Study Group. Insulin resistance in children and adolescents with type 1 diabetesmellitus: relation to obesity. Pediatr Diabetes 2005;6:5-12
23. Cheung MS, Bridges NA, Prasad SA, et al. Growth in children with cystic fibrosisrelated diabetes. Pediatr Pulmonol 2009; 44:1223-1225
24. Karges B, Neu A, Hofer SE, et al. [Frequency and influencing factors of ketoacidosis at diabetes onset in children and adolescentsda long-term study between 1995 and 2009]. Klin Padiatr 2011;223: 70-73
25. Neu A, Hofer SE, Karges B, Oeverink R, Rosenbauer J, Holl RW; DPV Initiative and the German BMBF Competency Network for Diabetes Mellitus. Ketoacidosis at diabetes onset is still frequent in children and adolescents: a multicenter analysis of 14, 664 patients from 106 institutions. Diabetes Care 2009;32:1647-164
26. O'Riordan SM, Dattani MT, Hindmarsh PC. Cystic fibrosis-related diabetes in childhood. Horm Res Paediatr 2010;73: 15-24
27. American Diabetes Association. Clinical Practice Recommendations-2010. Diabetes Care 2010;33(Suppl 1):S1-S10
28. Andersen HU, Lanng S, Pressler T, Laugesen CS, Mathiesen ER. Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications. Diabetes Care 2006;29:2660-2663
29. Schwarzenberg SJ, ThomasW, Olsen TW, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007;30:1056-1061
30. van den Berg JM, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HG. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J Cyst Fibros 2008;7:515-519
31. Holl RW, Heinze E, Wolf A, Rank M, Teller WM. Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis. Eur J Pediatr 1995;154: 356-361
32. Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump in treat cystic fibrosis related diabetes. J Cyst Fibros 2009;8:174-178
33. Nathan BM, Laguna T, Moran A. Recent trends in cystic fibrosis-related diabetes. Curr Opin Endocrinol Diabetes Obes 2010;17:335-341
34. Moran A, Pekow P, Grover P, et al.; Cystic Fibrosis Related Diabetes Therapy Study Group. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 2009;32:1783-1788
35. Moran A, Phillips J, Milla C. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care 2001;24:1706-1710
36. Onady GM, Langdon LJ. Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study. BMC Endocr Disord 2006;6:4
37. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 2003;26: 138-143
38. Spaans EA, Kleefstra N, van Hateren KJ, Aanstoot HJ, Bilo HJ, Brand PL. [Metformin in adolescents and adults with type 1 diabetes mellitus: not evidencebased]. Ned Tijdschr Geneeskd 2011; 155:A3166